June M Tordoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/273470/publications.pdf

Version: 2024-02-01

67 1,276 18 33 g-index
68 68 68 1635

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Identifying New Zealand Public Preferences for Pharmacist Prescribers in Primary Care: A Discrete Choice Experiment. Patient, 2022, 15, 77-92.	2.7	3
2	Identifying Community Pharmacist Preferences For Prescribing Services in Primary Care in New Zealand: A Discrete Choice Experiment. Applied Health Economics and Health Policy, 2021, 19, 253-266.	2.1	4
3	Examining non-medical prescribing trends in New Zealand: 2016–2020. BMC Health Services Research, 2021, 21, 418.	2.2	3
4	<p>Exploring Medicines Burden Among Adults in New Zealand: A Cross-Sectional Survey</p> . Patient Preference and Adherence, 2019, Volume 13, 2171-2184.	1.8	11
5	Patient-focused medicines information: General practitioners' and pharmacists' views on websites and leaflets. Health Education Journal, 2019, 78, 340-351.	1.2	7
6	Patients' views of general practitioners' provision of medicine information leaflets. Journal of Primary Health Care, 2019, 11, 359.	0.6	5
7	Doctors and pharmacists provision and opinions of medicines information leaflets in New Zealand. International Journal of Clinical Pharmacy, 2018, 40, 676-685.	2.1	3
8	Regulatory agencies' recommendations for medicine information leaflets: Are they in line with research findings?. Research in Social and Administrative Pharmacy, 2018, 14, 196-202.	3.0	14
9	Do health professionals tell patients what they want to know about their medicines?. Health Education Journal, 2018, 77, 762-777.	1.2	6
10	Non-medical prescribing in New Zealand: an overview of prescribing rights, service delivery models and training. Therapeutic Advances in Drug Safety, 2017, 8, 349-360.	2.4	30
11	†What do patients want?' Tailoring medicines information to meet patients' needs. Research in Social and Administrative Pharmacy, 2017, 13, 1186-1190.	3.0	47
12	Do Residents Need All Their Medications? A Cross-Sectional Survey of RNs' Views on Deprescribing and the Role of Clinical Pharmacists. Journal of Gerontological Nursing, 2017, 43, 13-20.	0.6	12
13	Geographic variation in psychotropic drug utilisation among older people in <scp>N</scp> ew <scp>Z</scp> ealand. Australasian Journal on Ageing, 2016, 35, 242-248.	0.9	3
14	General practitioners' insight into deprescribing for the multimorbid older individual: a qualitative study. International Journal of Clinical Practice, 2016, 70, 261-276.	1.7	48
15	Quality in residential care: exploring residents', family members', managers' and staff perspectives. Quality in Ageing and Older Adults, 2016, 17, 253-262.	0.8	4
16	Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand. International Journal of Clinical Pharmacy, 2016, 38, 941-949.	2.1	7
17	Impact of prescription charges on people living in poverty: A qualitative study. Research in Social and Administrative Pharmacy, 2016, 12, 893-902.	3.0	23
18	Examining potentially inappropriate prescribing in residential care using the STOPP/START criteria. European Geriatric Medicine, 2016, 7, 40-46.	2.8	10

#	Article	IF	CITATIONS
19	Temporal trends in the utilisation of preventive medicines by older people: A 9-year population-based study. Archives of Gerontology and Geriatrics, 2016, 62, 103-111.	3.0	14
20	Challenges and Enablers of Deprescribing: A General Practitioner Perspective. PLoS ONE, 2016, 11, e0151066.	2.5	148
21	Using an Electronic Decision Support Tool to Reduce Inappropriate Polypharmacy and Optimize Medicines: Rationale and Methods. JMIR Research Protocols, 2016, 5, e105.	1.0	10
22	Quality use of antipsychotic medicines inresidential aged care facilities in New Zealand. Journal of Primary Health Care, 2016, 8, 335.	0.6	2
23	One of us: Stories from two New Zealand rest homes. Journal of Aging Studies, 2015, 35, 135-143.	1.4	4
24	An International Comparison Study of Pharmacy Students' Achievement Goals and their Relationship to Assessment Type and Scores. American Journal of Pharmaceutical Education, 2015, 79, 35.	2.1	7
25	Poverty, medicines and health care: It's the little things…. Journal of Primary Health Care, 2015, 7, 170-1.	0.6	0
26	An international validation study of two achievement goal measures in a pharmacy education context. Advances in Medical Education and Practice, 2014, 5, 339.	1.5	8
27	Psychotropic Medicine Utilization in Older People in New Zealand from 2005 to 2013. Drugs and Aging, 2014, 31, 755-768.	2.7	21
28	Older people's experiences of medicine changes on leaving hospital. Research in Social and Administrative Pharmacy, 2014, 10, 791-800.	3.0	28
29	A systematic review and metaâ€analysis of pharmacistâ€led feeâ€forâ€services medication review. British Journal of Clinical Pharmacology, 2014, 77, 102-115.	2.4	148
30	Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand. International Journal of Clinical Pharmacy, 2014, 36, 503-512.	2.1	17
31	Pharmacists' performance of clinical interventions during adherence support medication reviews. Research in Social and Administrative Pharmacy, 2014, 10, 185-194.	3.0	16
32	Potentially inappropriate medicines in a cohort of communityâ€dwelling older people in <scp>N</scp> ew <scp>Z</scp> ealand. Geriatrics and Gerontology International, 2014, 14, 89-93.	1.5	47
33	New Zealand Health Care Editorial $\hat{A}-$ Prescription Charges: Prescription charge increase in new Zealand penalise the poor and sick. Journal of Primary Health Care, 2014, 6, 4.	0.6	6
34	Older people's perceptions of prescription medicine costs and related costs: a pilot study in New Zealand. Journal of Primary Health Care, 2014, 6, 295.	0.6	5
35	Prescription charge increases in New Zealand penalise the poor and sick. Journal of Primary Health Care, 2014, 6, 4-5.	0.6	1
36	Older people's perceptions of prescription medicine costs and related costs: a pilot study in New Zealand. Journal of Primary Health Care, 2014, 6, 295-303.	0.6	2

#	Article	IF	CITATIONS
37	The Authors' Reply to Wonder and Milne: "Comparing Subsidized Access to Medicines Across Payer Systems― Pharmacoeconomics, 2013, 31, 175-176.	3.3	1
38	General practitioners' views of pharmacists' current and potential contributions to medication review and prescribing in New Zealand. Journal of Primary Health Care, 2013, 5, 223-33.	0.6	9
39	Older people's attitudes towards their regular medicines. Journal of Primary Health Care, 2013, 5, 234-42.	0.6	10
40	KEY INFORMANTS' PERCEPTIONS OF HOW PHARMAC OPERATES IN NEW ZEALAND. International Journal of Technology Assessment in Health Care, 2012, 28, 367-373.	0.5	7
41	A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics, 2012, 30, 1051-1065.	3.3	26
42	Community pharmacists' perceptions of services that benefit older people in New Zealand. International Journal of Clinical Pharmacy, 2012, 34, 342-350.	2.1	9
43	General practitioners' perceptions of pharmacists' new services in New Zealand. International Journal of Clinical Pharmacy, 2012, 34, 364-373.	2.1	51
44	SimPharm: How pharmacy students made meaning of a clinical case differently in paper†and simulationâ€based workshops. British Journal of Educational Technology, 2011, 42, 865-874.	6.3	22
45	"lt's just routine.―A qualitative study of medicine-taking amongst older people in New Zealand. International Journal of Clinical Pharmacy, 2010, 32, 154-161.	1.4	46
46	Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007. International Journal of Clinical Pharmacy, 2010, 32, 386-393.	1.4	6
47	The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand. Value in Health, 2010, 13, 148-156.	0.3	23
48	Medicine-taking practices in community-dwelling people aged >=75 years in New Zealand. Age and Ageing, 2010, 39, 574-580.	1.6	60
49	Access to prescribing information for paediatric medicines in the USA: postâ€modernization. British Journal of Clinical Pharmacology, 2009, 67, 341-346.	2.4	12
50	Examining the first year of Medicines Use Review services provided by pharmacists in New Zealand: 2008. New Zealand Medical Journal, 2009, 122, 3566.	0.5	27
51	"Price Management―and Its Impact on Hospital Pharmaceutical Expenditure and the Availability of Medicines in New Zealand Hospitals. Value in Health, 2008, 11, 1214-1226.	0.3	17
52	Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998?2002. British Journal of Clinical Pharmacology, 2007, 63, 85-91.	2.4	16
53	Documenting pharmacist's clinical interventions in New Zealand hospitals. International Journal of Clinical Pharmacy, 2007, 30, 99-106.	1.4	11
54	Pediatric Licensing Status and the Availability of Suitable Formulations for New Medical Entities Approved in the United States Between 1998 and 2002. Journal of Clinical Pharmacology, 2006, 46, 1038-1043.	2.0	20

#	Article	IF	CITATIONS
55	Workforce and Service Delivery Analysis across New Zealand Hospital Pharmacy Departments. Journal of Pharmacy Practice and Research, 2006, 36, 271-274.	0.8	1
56	Pharmacoeconomics: a Reliable Tool for Decisions on New Medicines?. Journal of Pharmacy Practice and Research, 2006, 36, 12-15.	0.8	1
57	Continuation of Proton Pump Inhibitors from Hospital to Community. International Journal of Clinical Pharmacy, 2006, 28, 189-193.	1.4	68
58	Use of centrally developed pharmacoeconomic assessments for local formulary decisions. American Journal of Health-System Pharmacy, 2006, 63, 1613-1618.	1.0	10
59	The influence of PHARMAC's National Hospital Pharmaceutical Strategy on Quality Use of Medicines activities in New Zealand hospitals. New Zealand Medical Journal, 2006, 119, U2100.	0.5	1
60	Influence of the National Hospital Pharmaceutical Strategy on the Assessment of New Medicines in New Zealand Public Hospitals. Journal of Pharmacy Practice and Research, 2005, 35, 271-275.	0.8	1
61	Managing Prices for Hospital Pharmaceuticals: A Successful Strategy for New Zealand?. Value in Health, 2005, 8, 201-208.	0.3	11
62	Changes in availability of paediatric medicines in Australia between 1998 and 2002. British Journal of Clinical Pharmacology, 2005, 59, 736-742.	2.4	20
63	Effect of the Pediatric Exclusivity Provision on children's access to medicines. British Journal of Clinical Pharmacology, 2005, 59, 730-735.	2.4	34
64	Health Professionals: How Do They Assess New Medicines?. International Journal of Clinical Pharmacy, 2005, 27, 236-242.	1.4	3
65	Quality Use of Medicines activities in New Zealand hospitals from 2000 to 2002. New Zealand Medical Journal, 2005, 118, U1259.	0.5	4
66	Processes for the Assessment and Introduction of New Medicines in New Zealand Hospitals. Journal of Pharmacy Practice and Research, 2004, 34, 267-271.	0.8	3
67	Trends in accessibility to medicines for children in New Zealand: 1998-2002. British Journal of Clinical Pharmacology, 2003, 57, 322-327.	2.4	22